The acute effect of different NAD + precursors included in the combined metabolic activators

Xiangyu Li,Hong Yang,Han Jin,Hasan Turkez,Gurkan Ozturk,Hamdi Levent Doganay,Cheng Zhang,Jens Nielsen,Mathias Uhlén,Jan Borén,Adil Mardinoglu
DOI: https://doi.org/10.1016/j.freeradbiomed.2023.05.032
IF: 8.101
2023-06-04
Free Radical Biology and Medicine
Abstract:NAD + and glutathione precursors are currently used as metabolic modulators for improving the metabolic conditions associated with various human diseases, including non-alcoholic fatty liver disease, neurodegenerative diseases, mitochondrial myopathy, and age-induced diabetes. Here, we performed a one-day double blinded, placebo-controlled human clinical study to assess the safety and acute effects of six different Combined Metabolic Activators (CMAs) with 1 g of different NAD + precursors based on global metabolomics analysis. Our integrative analysis showed that the NAD + salvage pathway is the main source for boosting the NAD + levels with the administration of CMAs without NAD + precursors. We observed that incorporation of nicotinamide (Nam) in the CMAs can boost the NAD + products, followed by niacin (NA), nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), but not flush free niacin (FFN). In addition, the NA administration led to a flushing reaction, accompanied by decreased phospholipids and increased bilirubin and bilirubin derivatives, which could be potentially risky. In conclusion, this study provided a plasma metabolomic landscape of different CMA formulations, and proposed that CMAs with Nam, NMN as well as NR can be administered for boosting NAD + levels to improve altered metabolic conditions.
biochemistry & molecular biology,endocrinology & metabolism
What problem does this paper attempt to address?